Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. 1995

D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
Division of Psychology, Children's Hospital, Boston, MA 02115, USA.

OBJECTIVE We evaluated cognitive sequelae of treatment for childhood acute lymphoblastic leukemia (ALL). CNS therapy consisted of cranial irradiation (CRT) or no radiation. Children were also randomized to single intravenous high-dose methotrexate (HD-MTX) or conventional-dose methotrexate (CD-MTX) during induction, and all patients received intrathecal (IT) and systemic continuation chemotherapy. METHODS Sixty-six patients treated for ALL on Dana-Farber Cancer Institute protocol 87-01 were evaluated by standardized cognitive and achievement tests. These children had been assigned at diagnosis to a standard-risk (SR) or high-risk (HR) group and received no CRT or 18 Gy CRT, respectively. All patients were randomized to receive MTX during remission induction, either as CD-MTX (40 mg/m2) or HD-MTX (4 g/m2) with leucovorin rescue. RESULTS There was no difference in cognitive outcomes between radiated and unirradiated patients (P > .4). However, the HD-MTX/CRT combination was associated with decreased intelligence quotient (IQ estimate, 9.3 points) for girls only (P < .08). A specific deficit in verbal coding and memory was documented for all patients (P < .0001). CONCLUSIONS We conclude the following: (1) 18 Gy CRT per se was not an independent toxic agent for cognitive outcome; (2) HD-MTX during induction was associated with IQ decline in girls, but only when it was followed by CRT; and (3) impairment of verbal memory and coding was a consistent finding that was independent of CRT, which implicates some component of chemotherapy, possibly prednisone, as a CNS toxin.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D007360 Intelligence The ability to learn and to deal with new situations and to deal effectively with tasks involving abstractions.
D007361 Intelligence Tests Standardized tests that measure the present general ability or aptitude for intellectual performance. Mental Tests,Raven Test,Raven's Progressive Matrices,Intelligence Test,Mental Test,Raven Progressive Matrices,Ravens Progressive Matrices,Test, Intelligence,Test, Mental,Test, Raven
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D011878 Radiotherapy The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions. Radiotherapy, Targeted,Targeted Radiotherapy,Radiation Therapy,Radiation Therapy, Targeted,Radiation Treatment,Targeted Radiation Therapy,Radiation Therapies,Radiation Therapies, Targeted,Radiation Treatments,Radiotherapies,Radiotherapies, Targeted,Targeted Radiation Therapies,Targeted Radiotherapies,Therapies, Radiation,Therapies, Targeted Radiation,Therapy, Radiation,Therapy, Targeted Radiation,Treatment, Radiation
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
August 1984, American journal of diseases of children (1960),
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
September 2012, Journal of the National Cancer Institute,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
August 1996, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
January 2020, Scientific reports,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
June 2009, The New England journal of medicine,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
January 1976, Strahlentherapie,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
January 1998, Klinische Padiatrie,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
January 2009, Seminars in hematology,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
March 2014, Journal of pediatric hematology/oncology,
D P Waber, and N J Tarbell, and D Fairclough, and K Atmore, and R Castro, and P Isquith, and F Lussier, and I Romero, and P J Carpenter, and M Schiller
January 1991, Wiener klinische Wochenschrift,
Copied contents to your clipboard!